The consortium of the RISK-IR project brings together expertise from 13 research groups of 10 institutions from 7 European countries.
Click on their name for further information and on their logo to reach the site of each insitution.
The way in which management operates at the CNIO reflects the flexibility associated with a private organisation - such freedom owing itself to the especially created Foundation, along with the accountability expected of public organisational status, translating in the strict vigilance of all public funds received.
The mission of the CNIO is to conduct research of excellence and to bring the very latest technology in the field of cancer to the Spanish National Health System. With both goals in mind, strategic objectives for the CNIO were established:
The CNIO consists at present of seven research programmes (namely, Molecular Oncology, Structural Biology and Biocomputing, Cancer Cell Biology, Molecular Pathology, Human Cancer Genetics, Experimental Therapeutics and Clinical Research) and a core services programme (Biotechnology).
Led by Dr. Manuel Serrano, CNIO will input into WP3 by investigating short term responses of cancer relevant pathways in iPS cells and differentiated stem cells.
Manuel Serrano is Director of the Molecular Oncology Programme and Head of the Tumour Suppression Group. The strategic goals of his group are:
He has contributed to FP5 and FP6 projects (CELLAGE, INTACT, PROTEOMAGE) and currently holds an ERC Advanced Grant (CANCER&AGEING). Dr. Serrano has published all together a total of 157 articles. As of March 1 2012 Serrano’s publications received a total of 15.553 citations and have an accumulated Impact Factor index is of 1658.89. The “h” index of Manuel Serrano is 49.